421 related articles for article (PubMed ID: 16985239)
1. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
2. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
[TBL] [Abstract][Full Text] [Related]
3. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Kahán Z
Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
[No Abstract] [Full Text] [Related]
4. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
5. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
Bauerschlag D; Schem C; Maass N; Jonat W
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
8. Aromatase inhibitors in breast cancer: an overview.
Altundag K; Ibrahim NK
Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
[TBL] [Abstract][Full Text] [Related]
9. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
[No Abstract] [Full Text] [Related]
10. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
[No Abstract] [Full Text] [Related]
12. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Tuma RS
J Natl Cancer Inst; 2006 Jan; 98(2):86-7. PubMed ID: 16418506
[No Abstract] [Full Text] [Related]
13. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
[TBL] [Abstract][Full Text] [Related]
14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
15. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Poole R; Paridaens R
Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
[TBL] [Abstract][Full Text] [Related]
16. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Di Leo A; Buyse M
J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
[No Abstract] [Full Text] [Related]
17. Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Bria E; Carlini P; Cognetti F; Terzoli E; Giannarelli D
J Natl Cancer Inst; 2007 Jan; 99(2):176; author reply 176-7. PubMed ID: 17228003
[No Abstract] [Full Text] [Related]
18. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
Seo JH; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant endocrine therapy for breast cancer: don't ditch the switch!
Puhalla S; Jankowitz RC; Davidson NE
J Natl Cancer Inst; 2011 Sep; 103(17):1280-2. PubMed ID: 21859987
[No Abstract] [Full Text] [Related]
20. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Chlebowski RT; Col N
J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
